ClinicalTrials.gg
Status unknownNCT03960905Updated May 23, 2019

A Study the Population Pharmacokinetics of Children of Infectious Disease in Central Nervous System

An observational study in Central Nervous System Infection, sponsored by Wei Zhao. Status unknown at 1 site in China. Open to participants aged 29 Days to 18 Years. Per ClinicalTrials.gov, last updated 2019-05-23.

Sponsored by Wei Zhao · Observational

How we know

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
800
Ages
29 Days to 18 Years
Sex
All
01

Study summary

The investigators aim to study the population pharmacokinetics of children receiving the anti-infective drugs for treatment of infectious disease in central nervous system.

Read the detailed description

The investigators aim to study the population pharmacokinetics of children receiving the anti-infective drugs for treatment of infectious disease in central nervous system.In this study, the investigators will detect drug concentration in plasma by using residual blood samples of blood gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models.

02

Conditions studied

  • Central Nervous System Infection
03

In context

Central Nervous System Infections

41 studies on the registry are indexed under Central Nervous System Infections; 9 are open to participants now.

This study's planned enrollment of 800 is above the median of 486 across 24 observational studies indexed under Central Nervous System Infections.

Browse Central Nervous System Infections studies →

Lead sponsor

Wei Zhao is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
29 Days to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Children with infections of center nurous system therapies.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children (29 days-18 years old) with anti-infective therapy against infectious disease in central nervous system.
  • Clinical symptoms: acute onset, fever (axillary temperature 38 ℃ or higher), headache, altered level of consciousness, vomiting, irritability, sleepiness, low muscle tone, seizures, before the fontanelle full or uplift, positive meningeal stimulation;
  • Aboratory examination: CSF appearance change, CSF routine WBC >100 per ml, CSF routine WBC 10-100 per ml, glucose \<40mg/dl, protein >100mg/dl), positive detection of etiology (bacterial culture, antigen detection, gram staining).

Exclusion criteria

Exclusion Criteria:

  • encephalitis;
  • central nervous system infection complicated with tumor;
  • allergic to carbapenems or glycopeptide antibiotics;
  • other cases not suitable for enrollment (small sample size, incomplete clinical data, etc.).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
800 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Children with the usage of anti-infective drugs

    in conformity with the clinical practice

    Other: Children with the usage of anti-infective drugs

Interventions

  • OtherChildren with the usage of anti-infective drugs

    According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.

    Also known as: Cefepime (Maxipime®), ceftazidime, meropenem (Mepem®)

06

What researchers measure

Primary outcomes

  1. maximum concentration (Cmax)

    Cmax is a term used in pharmacokinetics refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose.

    Time frame: up to 4 weeks

Secondary outcomes

  1. time to achieve maximum concentration (Tmax)

    Tmax is the term used in pharmacokinetics to describe the time at which the Cmax is observed.

    Time frame: up to 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Department of Infectious Diseases, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health
    Beijing, Beijing 100045, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2019 (actual). Primary completion is estimated for Dec 2020, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2019
First posted
May 23, 2019
StartActual
Jan 1, 2019
Primary completionEst.
Dec 31, 2020
CompletionEst.
Dec 31, 2020
Last update
May 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03960905
Lead sponsor
Wei Zhao
Collaborators
Beijing Children's Hospital
Responsible party
Wei Zhao (Professor; Head of department of clinical pharmacy and pharmacology, Shandong University) — Sponsor-investigator
First posted
May 23, 2019
Start date
Jan 1, 2019
Primary completion
Dec 31, 2020 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
May 23, 2019

Study contacts

Zhao Wei, Ph.D
Contact
zhao4wei2@hotmail.com
053188383308

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion